SUCRAID
Drug
QOL Medical, LLC
Total Payments
$3.1M
Transactions
40,174
Doctors
9,825
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $1.9M | 18,947 | 6,124 |
| 2022 | $641,881 | 11,663 | 4,414 |
| 2021 | $342,655 | 9,514 | 3,850 |
| 2019 | $147,213 | 45 | 13 |
| 2018 | $51,230 | 5 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $1.4M | 147 | 46.3% |
| Food and Beverage | $880,441 | 39,365 | 28.8% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $454,367 | 211 | 14.8% |
| Honoraria | $197,588 | 131 | 6.5% |
| Travel and Lodging | $47,355 | 286 | 1.5% |
| Consulting Fee | $36,050 | 5 | 1.2% |
| Space rental or facility fees (teaching hospital only) | $28,500 | 10 | 0.9% |
| Education | $122.11 | 19 | 0.0% |
Payments by Type
General
$1.6M
40,027 transactions
Research
$1.4M
147 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| QOL Pediatric Sucraid | QOL Medical, LLC | $938,058 | 0 |
| Congenital Sucrase Isomaltase Deficiency (CSID) Screening Study in Adults > 18 years | QOL Medical, LLC | $131,143 | 0 |
| An Adult Pilot Study to Establish the Reference Ranges and Optimal Cut-offs for the Oral 50g Sucrose Challenge Test and the 13C-Sucrose Breath Test for CSID Cases (Previously Diagnosed Sucraid Responders) and Controls (GI Asymptomatic Healthy Volunteers) | QOL Medical, LLC | $80,140 | 0 |
| Sucrase-Isomaltase Deficiency in Irritable Bowel Syndrome and Diarrhea - Hiding in Plain Sight? | QOL Medical, LLC | $58,634 | 0 |
| Evaluation of a 7-Day Therapeutic Trial Dose of Commercial Sucraid (sacrosidase) Oral Solution for Alleviating Congenital Sucrase-Isomaltase Deficiency (CSID) Symptoms in Pediatric Subjects with Low, Moderate, and Normal Sucrase Levels | QOL Medical, LLC | $55,440 | 0 |
| SSDXA-14 | QOL Medical, LLC | $44,049 | 0 |
| FFPE/DAR | QOL Medical, LLC | $43,015 | 0 |
| Prospective evaluation of the prevalence of sucrose malabsorption in patients referred for testing for small intestinal bacterial overgrowth | QOL Medical, LLC | $19,012 | 0 |
| C13 TESTING FOR SIBO PATIENTS | QOL Medical, LLC | $16,437 | 0 |
| An Adult Pilot Study to Establish the Reference Ranges and Optimal Cut-offs for the Oral 50g Sucrose Challenge Test and the 13C-Sucrose Breath Test for CSID Cases (Previously Diagnosed Sucraid® Responders) and Controls (GI Asymptomatic Healthy Volunteers) | QOL Medical, LLC | $12,500 | 0 |
| Functional sucrase deficiency in short bowel syndrome patients with intestinal failure | QOL Medical, LLC | $10,000 | 0 |
| SID | QOL Medical, LLC | $5,723 | 0 |
| Prospective Evaluation of the Presence of Sucrose Malabsorption in Patients Referred for Testing for Small Intestinal Bacteria Overgrowth | QOL Medical, LLC | $3,700 | 0 |
Top Doctors Receiving Payments for SUCRAID — Page 3
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , MD PA | Gastroenterology | Miami, FL | $863.80 | 60 |
| , M.D | Gastroenterology | New York, NY | $842.60 | 31 |
| , DO | Gastroenterology | Syosset, NY | $823.13 | 25 |
| , MD | Gastroenterology | Charlotte, NC | $818.11 | 43 |
| , MD | Internal Medicine | Albany, NY | $806.93 | 31 |
| , MD | Gastroenterology | New York, NY | $806.05 | 30 |
| , M.D | Gastroenterology | Miami, FL | $798.00 | 60 |
| , MD | Specialist | New York, NY | $794.18 | 31 |
| , M.D | Gastroenterology | Conroe, TX | $792.74 | 28 |
| , M.D | Gastroenterology | Coral Gables, FL | $790.44 | 47 |
| , MD | Gastroenterology | Riverhead, NY | $771.54 | 24 |
| , M.D | Gastroenterology | Garden City, NY | $770.36 | 29 |
| , NP | Community Health | Oceanside, NY | $762.17 | 30 |
| , MD | Gastroenterology | New York, NY | $757.38 | 28 |
| , MD | Gastroenterology | Shenandoah, TX | $744.57 | 21 |
| , MD | Gastroenterology | New York, NY | $713.23 | 21 |
| , M.D | Internal Medicine | Los Angeles, CA | $712.60 | 36 |
| , M.D | Specialist | New York, NY | $710.48 | 20 |
| , MD | Pediatric Gastroenterology | Batavia, NY | $708.41 | 33 |
| , FNP-C | Family | Slidell, LA | $707.68 | 30 |
| , MD, MBA | Student in an Organized Health Care Education/Training Program | Charlotte, NC | $695.79 | 33 |
| , M.D | Gastroenterology | New York, NY | $684.14 | 27 |
| George Atia | — | Barrington, IL | $679.55 | 27 |
| , MD | Gastroenterology | Ann Arbor, MI | $677.69 | 19 |
| , M.D | Gastroenterology | New York, NY | $666.09 | 21 |
Ad
Manufacturing Companies
- QOL Medical, LLC $3.1M
Product Information
- Type Drug
- Total Payments $3.1M
- Total Doctors 9,825
- Transactions 40,174
About SUCRAID
SUCRAID is a drug associated with $3.1M in payments to 9,825 healthcare providers, recorded across 40,174 transactions in the CMS Open Payments database. The primary manufacturer is QOL Medical, LLC.
Payment data is available from 2018 to 2024. In 2024, $1.9M was paid across 18,947 transactions to 6,124 doctors.
The most common payment nature for SUCRAID is "Unspecified" ($1.4M, 46.3% of total).
SUCRAID is associated with 13 research studies, including "QOL Pediatric Sucraid" ($938,058).